The Enterprise Value as of December 2025 (TTM) for Aligos Therapeutics, Inc. (ALGS) is 26.21M

According to Aligos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 26.21M. This represents a change of -70.35% compared to the average of 88.40M of the last 4 quarters.

Aligos Therapeutics, Inc. (ALGS) Historical Enterprise Value (quarterly & annually)

How has ALGS Enterprise Value performed in the past?

The mean historical Enterprise Value of Aligos Therapeutics, Inc. over the last ten years is 7.50B. The current 26.21M Enterprise Value has changed -65.03% with respect to the historical average. Over the past ten years (40 quarters), ALGS's Enterprise Value was at its highest in in the December 2020 quarter at 21.54B. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.

Aligos Therapeutics, Inc. (ALGS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aligos Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Aligos Therapeutics, Inc. (ALGS) Average Enterprise Value

How has ALGS Enterprise Value performed in the past?

The current Enterprise Value of Aligos Therapeutics, Inc. (ALGS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Aligos Therapeutics, Inc. (ALGS) Enterprise Value vs. Peers

How is ALGS’s Enterprise Value compared to its peers?

Aligos Therapeutics, Inc.’s Enterprise Value is less than Mersana Therapeutics, Inc. (83.22M), greater than Kezar Life Sciences, Inc. (20.85M), less than FibroGen, Inc. (103.14M), greater than X4 Pharmaceuticals, Inc. (6.31M), greater than Tempest Therapeutics, Inc. (9.57M), greater than Barinthus Biotherapeutics plc (-33263316.00), greater than OnKure Therapeutics, Inc. (-34012234.00), less than CEL-SCI Corporation (51.39M), greater than INmune Bio, Inc. (23.33M), greater than Skye Bioscience, Inc. (15.30M),

Build a custom stock screener for Aligos Therapeutics, Inc. (ALGS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aligos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aligos Therapeutics, Inc. (ALGS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aligos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.